Dump

Load King and Custom Truck One Source to Showcase Electric and Hybrid Innovations at NTEA Work Truck Week 2024

Retrieved on: 
Wednesday, February 28, 2024

Load King and Custom Truck One Source, Inc. (NYSE: CTOS) are proud to announce their participation in the upcoming NTEA Work Truck Week, taking place from March 5-8, 2024, at the Indiana Convention Center, Indianapolis, Indiana.

Key Points: 
  • Load King and Custom Truck One Source, Inc. (NYSE: CTOS) are proud to announce their participation in the upcoming NTEA Work Truck Week, taking place from March 5-8, 2024, at the Indiana Convention Center, Indianapolis, Indiana.
  • This premier industry show serves as a platform for participating companies to exhibit their latest advancements in electric vehicle and hybrid technology.
  • Load King Voyager® I, 11’ Mechanics Truck: This unit showcases a hybrid solution with the Lightning PTO and Bergstrom eCoolPark electric, AC Cooling system.
  • Join us at NTEA Work Truck Week 2024 to experience the future of the work truck industry and discover how Load King and Custom Truck One Source are driving progress through innovation.

Atlas Lithium Corporation (ATLX) Lead Plaintiff Deadline Approaching: Contact Robbins LLP if You Incurred Significant Losses in Atlas Lithium Corporation

Retrieved on: 
Thursday, July 20, 2023

For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.

Key Points: 
  • For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • On May 4, 2023, Bleecker Street Research published a report entitled "Atlas Lithium (ATLX): First Comes The Pump … Now Here Comes the Dump."
  • What Now: Similarly situated shareholders may be eligible to participate in the class action against Atlas Lithium Corporation.
  • Shareholders who want to act as lead plaintiff for the class must file their papers by August 1, 2023.

Atlas Lithium Corporation (ATLX) Investor Alert: Shareholders with Significant Losses in ATLX Should Contact Robbins LLP Regarding the Class Action Against Atlas Lithium Corporation

Retrieved on: 
Wednesday, June 28, 2023

For more information, submit a form , email Aaron Dumas, Jr., or give us a call (800) 350-6003.

Key Points: 
  • For more information, submit a form , email Aaron Dumas, Jr., or give us a call (800) 350-6003.
  • On May 4, 2023, Bleecker Street Research published a report entitled "Atlas Lithium (ATLX): First Comes The Pump … Now Here Comes the Dump."
  • What Now: Similarly situated shareholders may be eligible to participate in the class action against Atlas Lithium Corporation.
  • Shareholders who want to act as lead plaintiff for the class must file their papers by August 1, 2023.

Atlas Lithium Corporation (ATLX) Equity Alert: Robbins LLP Urges Investors with Substantial Losses to Contact the Firm Regarding the Atlas Lithium Corporation Class Action

Retrieved on: 
Tuesday, June 20, 2023

For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.

Key Points: 
  • For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • On May 4, 2023, Bleecker Street Research published a report entitled "Atlas Lithium (ATLX): First Comes The Pump … Now Here Comes the Dump."
  • What Now: Similarly situated shareholders may be eligible to participate in the class action against Atlas Lithium Corporation.
  • Shareholders who want to act as lead plaintiff for the class must file their papers by August 1, 2023.

Atlas Lithium Corporation (ATLX) Class Action Alert: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Atlas Lithium Corporation Class Action

Retrieved on: 
Tuesday, June 13, 2023

Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Atlas Lithium Corporation (NASDAQ: ATLX) common stock between May 25, 2022 and May 3, 2023.

Key Points: 
  • Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Atlas Lithium Corporation (NASDAQ: ATLX) common stock between May 25, 2022 and May 3, 2023.
  • On May 4, 2023, Bleecker Street Research published a report entitled "Atlas Lithium (ATLX): First Comes The Pump … Now Here Comes the Dump."
  • What Now: Similarly situated shareholders may be eligible to participate in the class action against Atlas Lithium Corporation.
  • Shareholders who want to act as lead plaintiff for the class must file their papers by August 1, 2023.

Atlas Lithium Corporation (ATLX) Shareholder Notice: Robbins LLP Reminds Investors of Class Action Against Atlas Lithium Corporation

Retrieved on: 
Friday, June 9, 2023

SAN DIEGO, June 09, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Atlas Lithium Corporation (NASDAQ: ATLX) common stock between May 25, 2022 and May 3, 2023.

Key Points: 
  • SAN DIEGO, June 09, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Atlas Lithium Corporation (NASDAQ: ATLX) common stock between May 25, 2022 and May 3, 2023.
  • Atlas Lithium, formerly known as Brazil Minerals, is a mineral exploration and development company with lithium projects and exploration properties in other critical and battery minerals, including nickel, rare earths, graphite, and titanium.
  • On May 4, 2023, Bleecker Street Research published a report entitled "Atlas Lithium (ATLX): First Comes The Pump … Now Here Comes the Dump."
  • What Now: Similarly situated shareholders may be eligible to participate in the class action against Atlas Lithium Corporation.

Bronstein, Gewirtz & Grossman, LLC Notifies Atlas Lithium Corp. (ATLX) Investors of Class Action

Retrieved on: 
Thursday, June 8, 2023

Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Atlas Lithium Corp. ("Atlas Lithium" or the "Company") (NASDAQ: ATLX) and certain of its officers, on behalf of all persons and entities that purchased or otherwise acquired Atlas Lithium securities between March 25, 2022 and May 3, 2023, (the “Class Period”).

Key Points: 
  • Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Atlas Lithium Corp. ("Atlas Lithium" or the "Company") (NASDAQ: ATLX) and certain of its officers, on behalf of all persons and entities that purchased or otherwise acquired Atlas Lithium securities between March 25, 2022 and May 3, 2023, (the “Class Period”).
  • This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.
  • The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits.

Bronstein, Gewirtz & Grossman, LLC Notifies Atlas Lithium Corp. (ATLX) Investors of Class Action

Retrieved on: 
Wednesday, June 7, 2023

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Atlas Lithium Corp. ("Atlas Lithium" or the "Company") (NASDAQ: ATLX) and certain of its officers, on behalf of all persons and entities that purchased or otherwise acquired Atlas Lithium securities between March 25, 2022 and May 3, 2023, (the “Class Period”).

Key Points: 
  • Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Atlas Lithium Corp. ("Atlas Lithium" or the "Company") (NASDAQ: ATLX) and certain of its officers, on behalf of all persons and entities that purchased or otherwise acquired Atlas Lithium securities between March 25, 2022 and May 3, 2023, (the “Class Period”).
  • This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.
  • The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits.

Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Atlas Lithium Corporation (ATLX)

Retrieved on: 
Tuesday, June 6, 2023

Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Atlas Lithium Corporation (NASDAQ: ATLX) common stock between May 25, 2022 and May 3, 2023.

Key Points: 
  • Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Atlas Lithium Corporation (NASDAQ: ATLX) common stock between May 25, 2022 and May 3, 2023.
  • Atlas Lithium, formerly known as Brazil Minerals, is a mineral exploration and development company with lithium projects and exploration properties in other critical and battery minerals, including nickel, rare earths, graphite, and titanium.
  • On May 4, 2023, Bleecker Street Research published a report entitled "Atlas Lithium (ATLX): First Comes The Pump … Now Here Comes the Dump."
  • What Now: Similarly situated shareholders may be eligible to participate in the class action against Atlas Lithium Corporation.

NuCana Presents Favorable Data on NUC-3373 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022

Retrieved on: 
Monday, September 12, 2022

PARIS, Sept. 12, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced data from the ongoing NuTide:302 study of NUC-3373 in combination with other agents at the European Society for Medical Oncology (ESMO) Annual Meeting being held from September 9 to 13, 2022.

Key Points: 
  • Data presented at ESMO describe NUC-3373 plus leucovorin in combination with either oxaliplatin (NUFOX) or irinotecan (NUFIRI) in the dose-finding part of the study.
  • The disease control rates for the NUFOX and NUFIRI regimens were 80% and 55%, respectively.
  • With these data, NuCana has established the recommended Phase 2 dose for NUC-3373 as part of NUFOX and NUFIRI regimens.
  • TS is required to convert uridine (specifically dUMP) to thymidine (specifically dTMP), one of the four nucleotides that comprise DNA.